Long-Term Health Implications of Mitochondrial Peptides

Why the Steroid Checklist Doesn't Fit

When lifters ask about long-term risk, they usually mean the list that comes with anabolic steroids: suppressed natural testosterone, liver strain from oral compounds, and worse cholesterol numbers. Mitochondrial peptides are often pitched as a class that avoids those problems. Part of that is fair, and part rests on a claim that's only half true.

MOTS-c is a mitochondrial-derived peptide. A 2015 study in Cell Metabolism traced it to a short stretch of the mitochondrial genome (the 12S rRNA region), which means the body makes it naturally. SS-31 (elamipretide) is different. It's a synthetic peptide from the Szeto-Schiller family, built in a lab to bind a lipid inside mitochondria, and the body doesn't make it. So the idea that these compounds just "top up" something you already have applies at best to MOTS-c, and even there an injected dose isn't the same as what your muscles release during exercise.

The interest is still grounded in real biology. A 2013 review linked mitochondrial dysfunction, including oxidative stress and failing quality control, to sarcopenia (age-related muscle loss). A 2021 review in GeroScience argued that falling levels of mitochondrial-derived peptides such as MOTS-c and humanin may contribute to aging. That's a hypothesis built mostly on mouse and cell studies plus associations in human cohorts; nobody has tested it by giving the peptides to people for years. For how these compounds differ from anabolics in mechanism and results, see our comparison of mitochondrial peptides and anabolic steroids.

What We Can and Can't Cross Off the List

• Hormonal suppression. Neither peptide is known to act on the androgen receptor or the hypothalamic-pituitary-testicular axis, so there's no expected reason for testosterone shutdown or a post-cycle recovery period. That's an inference from mechanism. We found no study that measured testosterone in people using either compound long term.
• Liver. The classic liver risk comes from 17-alpha-alkylated oral steroids, and these peptides are injected. The closest human data for MOTS-c comes from CB4211, a modified analog rather than MOTS-c itself. In a four-week trial in 20 adults with obesity and fatty liver disease, 25 mg of CB4211 by daily subcutaneous injection lowered the liver enzymes ALT and AST compared with placebo, according to the developer's 2021 topline release. Liver fat fell by about the same amount in both groups. A small, short, company-reported study of a different molecule supports "no obvious liver signal", not "safe for the liver".
• Heart. SS-31 is often described as cardioprotective, but the human trials don't show that. In the EMBRACE STEMI Phase 2a trial, a one-hour intravenous infusion given during heart-attack treatment didn't reduce infarct size. In the PROGRESS-HF Phase 2 trial, 71 people with heart failure received placebo, 4 mg, or 40 mg of elamipretide daily for 28 days, and heart volumes and pumping function didn't improve compared with placebo. The drug was well tolerated in both trials. Heart protection seen in animal studies hasn't carried over to people so far.

What the Longer-Term Evidence Shows

The two peptides come at mitochondrial health from different directions: MOTS-c as a signal that changes metabolism across the body, SS-31 as a molecule that sits on the inner mitochondrial membrane.

MOTS-c: a metabolic signal, studied mostly in mice

In the 2015 study, MOTS-c acted mainly on skeletal muscle. It inhibited the folate cycle in a way that switched on AMPK, the cell's energy sensor, and treated mice were protected from insulin resistance caused by aging or a high-fat diet, and from diet-induced obesity. A 2021 study in Nature Communications found that MOTS-c improved physical performance in young, middle-aged, and old mice, and that intermittent treatment (three times a week) started late in life increased physical capacity and healthspan. The same study found that exercise raises people's own MOTS-c levels in muscle and blood. A 2015 letter in Aging Cell proposed that a MOTS-c gene variant common in Northeast Asia might contribute to longevity in Japan, which its authors called a suggestion needing more research.

The human side is thin. As of October 2026, we found no peer-reviewed study that gave native MOTS-c to people. The analog CB4211 is no longer in development: in a 2023 SEC filing, its developer CohBar said the trial formulation wasn't suitable to take further and that the company it was merging into didn't plan to continue its drug candidates. Users on peptide forums describe a wide range of MOTS-c schedules, often a few injections a week, and many mention injection-site reactions. None of those schedules has been tested in a trial.

SS-31: membrane protection, with mixed human trials

A 2014 review by Hazel Szeto, whose lab developed SS-31, explains the mechanism. SS-31 binds cardiolipin, a lipid found only in the inner mitochondrial membrane. That stops cardiolipin from turning cytochrome c into a damaging peroxidase and helps preserve the membrane folds (cristae) where ATP is made. Extensive animal studies support this, which is why the compound draws so much interest in aging research.

SS-31 is also the only peptide discussed here with an FDA approval. On September 19, 2025, the FDA granted accelerated approval to elamipretide, sold as Forzinity, to improve muscle strength in people with Barth syndrome weighing at least 30 kg. The approval rests on one trial of 12 males. During its 28-week controlled phase, 40 mg once daily by subcutaneous injection wasn't better than placebo on either primary endpoint (6-minute walk distance and fatigue). Knee-extensor strength rose during the open-label extension, and the FDA requires a confirmatory randomized trial.

The longest controlled data come from ReCLAIM-2, a 48-week Phase 2 trial of 40 mg daily in 176 people with dry age-related macular degeneration. It missed both primary endpoints but slowed loss of the retina's ellipsoid zone by 43% compared with placebo. The authors say that measure will be the primary endpoint in Phase 3.

For long-term use, the clearest safety signal is at the injection site. In the Barth trial, all 12 patients on elamipretide had injection-site redness, against 3 of 12 on placebo, and the FDA lists allergic reactions, some serious, as a risk. In ReCLAIM-2, adverse events occurred in 86% of the elamipretide group and 71% of the placebo group, mostly at the injection site. Users on peptide forums commonly report SS-31 doses of a few milligrams a day, roughly a tenth of the trial dose, in healthy adults, a population no trial has studied.

The Known Unknowns (And the Real Risk)

Nobody has run a 10- or 20-year controlled study of either peptide in healthy adults, and nobody is likely to. A few open questions matter most.

Feedback on the body's own production. Nobody knows whether regular MOTS-c injections lower the amount your mitochondria make. The same goes for retrograde signaling, the messages mitochondria send back to the cell nucleus. MOTS-c changes nuclear gene expression in mice, which is the point, but what years of extra signaling do in people hasn't been studied.

Doses and populations don't match. The SS-31 trials studied people with serious disease, mostly at 40 mg a day. Healthy lifters using a few milligrams aren't represented in that data, for benefit or for harm.

Product quality. For anyone buying gray-market vials, this may be the most immediate risk. A preprint (not yet peer-reviewed) that re-analyzed 6,441 independent test results across 14 peptides found that 41.6% to 71.1% failed basic quality criteria, depending on how strict the standard was, and that 15% of the samples tested for endotoxin had measurable contamination. Neither MOTS-c nor SS-31 was among the 14 compounds, so there's no equivalent data for them. FDA's August 2026 warning letters treat research-use-only SS-31 as an unapproved new drug and point out that injectable products bypass some of the body's defenses against toxins and microbes. Our page on why peptide synthesis quality matters covers what lab testing can and can't catch.

Tested athletes face a separate set of rules, covered in our page on MOTS-c, SS-31 and anti-doping rules.

What to Watch Next

• Forzinity's confirmatory trial. The FDA requires a randomized, placebo-controlled trial to confirm that the knee-strength changes translate into real benefit for people with Barth syndrome.
• SS-31 in dry macular degeneration. The Phase 3 program uses ellipsoid-zone loss as its primary endpoint. Results would add more controlled, long-duration exposure data.
• MOTS-c compounding. In July 2026, an FDA advisory committee voted 7-5 (two abstentions) to recommend adding MOTS-c to the list of substances pharmacies may compound, even though FDA's briefing materials stressed gaps in human safety data, according to a law-firm summary. The vote is advisory; FDA must complete rulemaking before anything changes.
• A published human MOTS-c trial. Until one exists, claims about long-term benefit in people are extrapolations from mice. For the broader aging picture, see our page on mitochondrial health and muscle preservation with age.